Ochocka M, Matysiak M, Newecka-Samól T, Kulus M, Armata J, Balwierz W, Bogusławska-Jaworska J, Chybicka A, Jackowska T, Jakowicka M
Katedry i Kliniki Hematologii i Chorób Rozrostowych AM, Warszawie.
Pol Tyg Lek. 1992;47(16-17):350-3.
Within the past 16 years, 2004 children with the acute lymphoblastic leukemia were treated at the Centres of the Polish Pediatric Study Group. The treatment was completed in 887 patients (44.3%) with the first remission. Recurrence was noted in 180 children (20.3%). This group was analysed in view of the type of therapy and its effect on the survival rate, significance of recurrence following therapy, character and localization of recurrent disease, and further fate of patients. It was found, that patients with isolated late nuclear recurrence have greatest chances to achieve subsequent remission. Most frequent and severe is recurrent bone marrow involvement which requires intensive chemotherapy combined with bone marrow transplantation due to unfavourable prognosis. Patients with the first recurrence of the acute lymphoblastic leukemia have a chance to achieve subsequent remission and long-term survival.
在过去16年中，波兰儿科研究组各中心对2004例急性淋巴细胞白血病患儿进行了治疗。887例患者（44.3%）首次缓解后完成了治疗。180名儿童（20.3%）出现复发。对该组患者从治疗类型及其对生存率的影响、治疗后复发的意义、复发性疾病的特征和部位以及患者的后续转归等方面进行了分析。结果发现，孤立性晚期核复发的患者获得后续缓解的机会最大。最常见且最严重的是复发性骨髓受累，由于预后不良，需要强化化疗并联合骨髓移植。急性淋巴细胞白血病首次复发的患者有机会获得后续缓解和长期生存。
